...
首页> 外文期刊>Molecules >Repeated Oral Administration of Oleanolic Acid Produces Cholestatic Liver Injury in Mice
【24h】

Repeated Oral Administration of Oleanolic Acid Produces Cholestatic Liver Injury in Mice

机译:重复口服齐墩果酸可在小鼠中产生胆汁淤积性肝损伤。

获取原文

摘要

Oleanolic acid (OA) is a triterpenoid and a fantastic molecule with many beneficial effects. However, high-doses and long-term use can produce adverse effects. This study aimed to characterize the hepatotoxic potential of OA. Mice were given OA at doses of 100–3,000 µmol/kg (45–1,350 mg/kg), po for 10 days, and the hepatotoxicity was determined by serum biochemistry, histopathology, and toxicity-related gene expression via real-time RT-PCR. Animal body weight loss was evident at OA doses of 1,000 µmol/kg and above. Serum alanine aminotransferase activities were increased in a dose-dependent manner, indicative of hepatotoxicity. Serum total bilirubin concentrations were increased, indicative of cholestasis. OA administration produced dose-dependent pathological lesions to the liver, including inflammation, hepatocellular apoptosis, necrosis, and feathery degeneration indicative of cholestasis. These lesions were evident at OA doses of 500 µmol/kg and above. Real-time RT-PCR revealed that OA produced dose-dependent increases in acute phase proteins (MT-1, Ho-1, Nrf2 and Nqo1), decreases in bile acid synthesis genes (Cyp7a1 and Cyp8b1), and decreases in liver bile acid transporters (Ntcp, Bsep, Oatp1a1, Oatp1b2, and Ostβ). Thus, the clinical use of OA and OA-type triterpenoids should balance the beneficial effects and toxicity potentials.
机译:齐墩果酸(OA)是一种三萜类化合物,是一种奇妙的分子,具有许多有益的作用。但是,高剂量和长期使用会产生不利影响。这项研究旨在表征OA的肝毒性潜力。给小鼠口服OA,剂量为100-3,000 µmol / kg(45-1,350 mg / kg),口服10天,并通过血清生化,组织病理学和通过实时RT- PCR。在OA剂量为1,000 µmol / kg及以上时,动物体重明显减轻。血清丙氨酸氨基转移酶活性以剂量依赖性方式增加,表明肝毒性。血清总胆红素浓度增加,表明胆汁淤积。 OA的给药对肝脏产生剂量依赖性的病理损伤,包括炎症,肝细胞凋亡,坏死和表明胆汁淤积的羽毛状变性。在500 µmol / kg或更高的OA剂量下,这些病变很明显。实时RT-PCR显示,OA在急性期蛋白(MT-1,Ho-1,Nrf2和Nqo1)中产生剂量依赖性增加,在胆汁酸合成基因(Cyp7a1和Cyp8b1)中减少,并在肝胆汁酸中减少转运蛋白(Ntcp,Bsep,Oatp1a1,Oatp1b2和Ostβ)。因此,OA和OA型三萜类化合物的临床应用应在有益效果和潜在毒性之间取得平衡。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号